Immunotherapy related myocarditis, colitis, uveitis, or pneumonitis.
Prior treatment with immunotherapy
Chemotherapy, immunotherapy or anticancer agents within 4 weeks
Immunotherapy
No prior immunotherapy allowed or prior alkylating agents or prior radiation to the brain
Prior immunotherapy is allowed.
Participants in all combination therapy arms must not have a history of exposure to an immunotherapy experiencing an immune-mediated adverse event that required permanent discontinuation of the immunotherapy.
Concurrent immunotherapy is allowed
Other active malignancy requiring therapy such as radiation, chemotherapy, or immunotherapy.
Immunotherapy less than or equal to 4 weeks prior to registration
Prior immunotherapy including sipuleucel-T
No prior exposure to immunotherapy agents
Prior treatment with any immunotherapy
Must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy.
Patients receiving immunotherapy for non-cancer related treatment within < 4 weeks of first planned dose of study treatment will be excluded.
Received chemotherapy/immunotherapy in the last 4 weeks
Concomitant chemotherapy, radiation therapy, or immunotherapy
For post immunotherapy patients with NSCLC all of the following apply:
For other post immunotherapy patients all of the following must apply:
?28 days for a prior immunotherapy. No prior therapy with check point inhibitors, costimulatory agonists or immunomodulatory agents is allowed.
Actively receiving chemo-immunotherapy
Patients who have received any prior immunotherapy
Patients who have received any cytotoxic therapy, immunotherapy, antitumor vaccines or monoclonal antibodies in the 4 weeks prior to the start of the study
Patients that have undergone Tyrosinase immunotherapy
Immunotherapy-naive.
Prior treatment with adenovirus-based vectors immunotherapy
Cohort #1: received only frontline CD20-directed immunotherapy with anthracycline- or anthracenedione-based multi-agent chemotherapy for patients with DLBCL; monotherapy rituximab or other CD20-directed immunotherapy prior to frontline chemotherapy, as maintenance therapy, and radiotherapy in a limited field or as a part of the frontline treatment plan are permitted; last treatment dose should be 3 weeks before start of study treatment
Chemotherapy or immunotherapy within 3 weeks prior to start of hu3F8
History of prior immunotherapy within the last 3 years (immunotherapy allowed for lead-in cohort in castration resistant disease)
Prior immunotherapy including sipuleucel-T
Chemotherapy or immunotherapy =< 28 days prior to registration
Patients may have had no more than one prior line of chemotherapy or immunotherapy in the metastatic setting; at least 14 days must have elapsed from the last chemo/immunotherapy administration until the start of protocol treatment, and patients must have recovered from the side effects of any of these agents
Received systemic treatment for cancer, including immunotherapy, within 28 days prior to initiation of conditioning chemotherapy administration within this protocol
Patients who have had administration of chemotherapy, target therapy, and/or immunotherapy within the last 4 weeks before the first OBP-301 administration.
Patients may have received prior immunotherapy
Prior chemotherapy or immunotherapy will be allowed if new or persistent measurable site(s) of disease are present
Prior immunotherapy or chemotherapy is allowed as long as > 14 days prior to enrollment
Chemotherapy or immunotherapy within 3 weeks prior to the first dose of vaccine
Patients with exposure to prior immunotherapy are not eligible
Prior chemotherapy, radiation, sipuleucel-T or other experimental immunotherapy less than 4 weeks prior to the start of study medication.
Must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy.
Ongoing systemic therapy for prostate cancer including, but not limited to:\r\n\t* Immunotherapy (e.g. sipuleucel-T, ipilimumab)\r\n\t* Non-protocol prescribed chemotherapy (e.g. cabazitaxel)
Be within 6 months (+/-1 week) between last dose of an immunotherapy agent and study enrollment\r\n* Patients may continue with maintenance immunotherapy as part of standard of care therapy while receiving radiation
Ongoing immunotherapy (checkpoint inhibition, antigen immunotherapy that would be scheduled to continue concomitantly to the study).
Have received biologic therapy, including immunotherapy, < 28 days prior to C1D1;
Received intervening intravesical chemotherapy or immunotherapy from the time of most recent cystoscopy / Transurethral Resection of Bladder Tumor (TURBT) to starting study treatment
Immunotherapy (e.g. tumor vaccine) (At least 42 days since last dose of immunotherapy agent(s) prior to first dose of tazemetostat)
Patients will be excluded if there is a plan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study period
Previous use of indoximod or tergenpumatucel-L immunotherapy.
Patients that have previously progressed on immunotherapy such as ipilimumab will be eligible
Previous chemotherapy/immunotherapy within 3 weeks before study entry
Chemotherapy, biologics, immunotherapy, vaccine, cytokine therapy within 4 weeks prior to enrollment
Chemotherapy, radiation, or immunotherapy, within 2 weeks prior to study entry, other than those specified in the inclusion criteria (hydroxyurea and hypomethylating agents)
Patients who have had any prior treatment for CLL, including chemotherapy, corticosteroids, biologic therapy, or immunotherapy are NOT eligible for participation
Patients must not have any significant toxicity associated with prior surgery, radiation therapy, chemotherapy, or immunotherapy, per principal investigator (PI) discretion
Patients who have received prior immunotherapy
No chemotherapy or immunotherapy for a minimum of three weeks prior to start of hu3F8
Prior neurologic toxicity to previous immunotherapy
Those receiving prior immunotherapy must meet all of the following conditions:
Require concomitant chemotherapy, radiation therapy, or immunotherapy. Hydroxyurea is allowed up to the evening before starting (but not within 12 hours) of starting treatment on either arm.
Patients who have received prior immunotherapy
Prior treatment with other immunotherapy, including antibodies, is allowed
>= 3 weeks between completion of chemotherapy or immunotherapy and first (1st) vaccination
Has had prior chemotherapy, radiation therapy, or immunotherapy for the diagnosis of iBCL
Subjects who have received prior immunotherapy may be eligible
Less than 3 weeks since prior chemotherapy, radiation therapy, or immunotherapy. However, hydroxyurea is permitted up to 24 hours before the study is initiated;
Concurrent immunotherapy (including monoclonal antibodies),during or within 30 days prior to start of study drug
Patients must have received previous systemic therapy to include: a regimen of chemotherapy, immunotherapy including anti-PDL or anti-PD-L1 therapies, combined chemotherapy and immunotherapy, provided treatment was discontinued >= 2 weeks prior to initiation of treatment on the present protocol
Treatment with prior chemotherapy, monoclonal antibodies, other protein or peptide therapeutics or anticancer immunotherapy within 21 days of the first dose of study drug
Systemic chemotherapy or immunotherapy within 14 days of enrollment;
Antibodies or immunotherapy within 6 weeks before the first dose of study treatment.
Naïve to prior chemotherapy or immunotherapy (i.e., this is a first-line systemic therapy study).
Prior immunotherapy
Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy\r\n* Myelosuppressive chemotherapy: must not have received chemotherapy within 2 weeks of enrollment and within 2 week of starting protocol therapy\r\n* Hematopoietic growth factors: at least 7 days since the last dose of growth factor therapy for both enrollment on study and for commencement of protocol therapy\r\n* Immunotherapy: patients may not have received immunotherapy within 3 weeks of enrollment and within 6 weeks of commencing protocol therapy
Prior investigational immunotherapy
Immunotherapy (e.g., tumor vaccine) At least 6 weeks since last dose of immunotherapy agent(s) prior to first dose of tazemetostat)
Received only frontline CD20-directed immunotherapy with anthracycline- or anthracenedione-based multi-agent chemotherapy. Monotherapy rituximab or other CD20-directed immunotherapy as maintenance therapy prior to frontline chemotherapy, and radiotherapy in a limited field or as part of the frontline treatment plan are permitted.
Prior platinum chemotherapy or immunotherapy
Previous immunotherapy
Any other chemotherapy, immunotherapy or anticancer agents within 2 weeks of the first dose of study treatment.
EXCLUSION FOR TREATMENT: Prior neurologic toxicity to previous immunotherapy
Prior immunotherapy with CRS-207 or any other Listeria-based agent, therapeutic cancer vaccine, or adoptive T cell immunotherapy
Prior immunotherapy will be permitted; however, any prior immunotherapy must be discontinued at least 2 weeks before peptide vaccine administration; non-immunologic therapy may be continued
Systemic anticancer therapy (chemotherapy, “biologics”, immunotherapy) less than two weeks prior to starting radiation
Immunotherapy [mAbs, Interferons, Cytokines (except GCSF)]
Participation in any other immunotherapy treatment, that in the opinion of the principal investigator would be unsafe to receive further checkpoint blockade immunotherapy.
Receiving concomitant chemotherapy, radiation therapy, or immunotherapy during the duration of treatment on protocol, or within 21 days prior to enrollment
History of prior immunotherapy within the last 3 years
Patient has had any prior intravesical chemotherapy, immunotherapy, or previous exposure to apaziquone.
The patient must not have received any immunotherapy for their brain tumor
Prior chemotherapy, radiation therapy, or immunotherapy for prostate cancer
Must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy
Discontinuation of all prior chemotherapy, immunotherapy, or biological therapy at least 3 weeks prior to the first dose of investigational product is required.
Radiation, chemotherapy, or immunotherapy or any other approved anticancer therapy =< 2 weeks prior to day -7 (beginning of loading phase)
Any immunotherapy within 4 weeks of first dose of study drug.
Treatment with chemotherapy, radiation therapy, or other immunotherapy =< 4 weeks prior to registration
Received any other therapeutic investigational agent within 30 days of screening, except for immunotherapy. Patients with previous immunotherapy are not eligible regardless of timing.
Any immunotherapy within 4 weeks of first dose of study drug.
Willingness to discontinue any cytotoxic chemotherapeutic agents, immunotherapy and biologic therapy at least 2 weeks prior to the start of RT.
Receiving concomitant chemotherapy, radiation therapy, or immunotherapy during the duration of treatment on protocol
Naïve untreated patients or patients who have progressed on or after prior first line immunotherapy for resectable locally advanced or metastatic melanoma; prior adjuvant therapy is permitted (e.g. IFN, IL-2 therapy, any other immunotherapy, radiotherapy or chemotherapy), except the administration of BRAF or MEK inhibitors
Any previous systemic chemotherapy treatment, extensive radiotherapy or investigational agent other than immunotherapy, or patients who have received more than one line of immunotherapy for locally advanced unresectable or metastatic melanoma; Ipilimumab (adjuvant) or other immunotherapy treatment must have ended at least 6 weeks prior to randomization
History of prior immunotherapy within the last 3 years
Treatment with an immunotherapy within 30 days
Prior sipuleucel-T treatment or investigational immunotherapy.
Patients with washout period < 6 weeks from the last dose of ipilimumab or other immunotherapy.
No chemotherapy or immunotherapy for a minimum of three weeks prior to study enrollment
Previous immunotherapy treatment for metastatic disease in the preceding 2 months; Note: immunotherapy in the adjuvant setting is allowed
Prior chemotherapy, radiation therapy, immunotherapy, or biotherapy for current breast cancer.
ELIGIBILITY PRIOR TO POST-CHEMOTHERAPY IMMUNOTHERAPY:
Patients will be excluded if there is a plan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study period
Patients will be excluded if there is a plan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study period.
Plan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study period.
Patients with washout period < 6 weeks from the last dose of ipilimumab or other immunotherapy
Prior immunotherapy (e.g. sipuleucel-T), and chemotherapy are permitted (4 week washout period from chemotherapy)
Prior immunotherapy is allowed
At least 2 weeks since the last chemotherapy, radiation therapy, immunotherapy or any investigational products
Other chemotherapy (e.g., mitomycin-C, nitrosourea) or immunotherapy (e.g., antibody, cytokine) within 4 weeks
Subjects who have received certain prior immunotherapy or had toxicities relating to prior immunotherapy may not be permitted to enroll. o Must not have required the use of additional immunosuppression other than corticosteroids for the management of an adverse event.
Any previous systemic therapy for B-cell NHL, including chemotherapy, immunotherapy, or steroids
Prior chemotherapy, immunotherapy, investigational therapeutic agent, or other therapy used to treat HCC within 4 weeks before the first scheduled administration of RO7070179.
Patients receiving systemic anticancer therapy (chemotherapy, “biologics”, immunotherapy) less than 2 weeks prior to starting radiation
Approved anticancer therapy including chemotherapy or immunotherapy.
History of any of the following toxicities associated with a prior immunotherapy:
Immunotherapy for cancer within 4 weeks of initial study treatment
Subjects who have received anti-cancer therapies within 2 weeks of the start of study drug (including chemotherapy, radiation therapy, immunotherapy, etc.).
Patients may have had prior chemotherapy or immunotherapy (vaccines, interferon, ipilimumab, or IL-2) with progression or persistent disease
Treatment of primary tumor within 4 weeks of Day 1 Week 1 with surgery, radiation, chemotherapy or immunotherapy
Patients must not have received any cytotoxic therapy, immunotherapy, antitumor vaccines or monoclonal antibodies in the 4 weeks prior to the start of the study
No prior chemotherapy, radiation therapy or immunotherapy for DLBCL; a short course (< 2 weeks) of corticosteroids is allowed for symptom control
Anticancer chemotherapy or immunotherapy during the study or within 4 weeks prior to the first dose of study drug
melanoma: at least 1 prior treatment (including immunotherapy).
CONTROL (HEALTHY) GROUP: Never received chemotherapy, radiation therapy, immunotherapy, or had breast surgery
No recent or planned immunotherapy
Have undergone treatment of hormone therapy, immunotherapy, chemotherapy and/or radiation for any malignancies within the past 2 years
The subject has had preoperative chemotherapy, immunotherapy, or radiation therapy within the 30 days prior to Lymphoseek administration
prior immunotherapy
Immunotherapy: ?42 days after completion of immunotherapy
